These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22352257)

  • 21. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
    Rosenberg C; Lauritzen L; Brix J; Jørgensen JB; Kofod P; Bayer LB
    Psychopharmacol Bull; 2007; 40(1):63-73. PubMed ID: 17285097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction. Overview of citalopram.
    Lippa AS; Beer B; Cancro R
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):1S-3S. PubMed ID: 10507504
    [No Abstract]   [Full Text] [Related]  

  • 23. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Escitalopram: a chiral agent for treatment of depression].
    Overlack M; Davids E; Gastpar M
    Med Monatsschr Pharm; 2004 May; 27(5):148-51. PubMed ID: 15171592
    [No Abstract]   [Full Text] [Related]  

  • 25. Escitalopram ameliorates prolonged depression with psychotic features induced by interferon therapy for hepatitis C infection: report of 2 cases.
    Kajitani K; Kanba S
    Psychosomatics; 2013; 54(5):506-7. PubMed ID: 23845321
    [No Abstract]   [Full Text] [Related]  

  • 26. Citalopram-induced hallucinations and delusions in a young adult.
    Capaldi VF; Carr RB
    Gen Hosp Psychiatry; 2010; 32(6):648.e1-3. PubMed ID: 21112465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study.
    Shoval G; Nahshoni E; Gothelf D; Manor I; Golobchik P; Zemishlany Z; Weizman A; Zalsman G
    Clin Neuropharmacol; 2011; 34(5):182-5. PubMed ID: 21926484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial.
    Noorbala AA; Akhondzadeh S; Tahmacebi-Pour N; Jamshidi AH
    J Ethnopharmacol; 2005 Feb; 97(2):281-4. PubMed ID: 15707766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram.
    Håkanson R
    Pharmacol Toxicol; 2002 Jan; 90(1):3-4. PubMed ID: 12005110
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
    J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible escitalopram-induced hypothyroidism.
    Eker SS; Akkaya C; Ersoy C; Sarandol A; Kirli S
    Gen Hosp Psychiatry; 2010; 32(5):559.e5-7. PubMed ID: 20851281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment.
    Barim AO; Aydin S; Colak R; Dag E; Deniz O; Sahin I
    Clin Biochem; 2009 Jul; 42(10-11):1076-81. PubMed ID: 19272368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [St. John's Wort for depression. 900 mg per day should an effective dose].
    MMW Fortschr Med; 2002 May; Suppl 2():87. PubMed ID: 12070867
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citalopram-induced diplopia.
    Dorell K; Cohen MA; Huprikar SS; Gorman JM; Jones M
    Psychosomatics; 2005; 46(1):91-3. PubMed ID: 15765832
    [No Abstract]   [Full Text] [Related]  

  • 40. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E; Niemi H
    Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.